GRCE: חוב כולל להון Grace Tx

Grace Therapeutics, Inc. (GRCE) is developing drugs for the therapy of rare nervous system pathologies, expanding its sales presence in Europe and the US to minimize regional insurance risks. Management is focused on patenting developments and ensuring regulatory compliance. The visualization of the Debt/Equity market value is 0.00. Growth prospects are based on the repurposing of molecules for the treatment of neuralgia and ataxia via an expedited FDA approval mechanism.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to shareholders' equity, determining the degree of financial leverage and the business's dependence on external borrowing. By analyzing the total debt/equity chart, an investor can assess the resilience of Grace Therapeutics, Inc. (GRCE) to the binary risks associated with a narrow specialization in orphan diseases, where high leverage in the absence of market sales critically increases the risk of bankruptcy.